Randomized Clinical Trials: Design, Practice and Reporting

Randomized Clinical Trials: Design, Practice and Reporting

Volumn , Issue , 2011, Pages

  Machin, David ^a,b   Fayers, Peter M ^c,d  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891584135     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470686232     Document Type: Book

References (193)

1. Advanced Ovarian Trialist Group (1991) Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. BMJ, 303, 884-893. [14]
2. Allan, L., Hays, H., Jensen, N.-H., de Waroux, B.L.P., Bolt, M., Donald, R. and Kalso, E. (2008) Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ, 322, 1-7. [12]
3. Al-Sarraf, M., Pajak, P.F., Cooper, J.S., Mohiuddin, M., Herskovic, A. and Ager, P.J. (1990) Chemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma: a radiation therapy oncology group study. Journal of Clinical Oncology, 8, 1342-1351. [2]
4. Altman, D.G., (1991) Practical Statistics for Medical Research. Chapman and Hall, London. [8]
5. Altman, D.G., Gore, S.M., Gardner, M.J. and Pocock, S.J. (2000) Statistical guidelines for contributors to medical journals. In Statistics with Confidence, 2nd edn (eds D.G. Altman, D. Machin, T.N. Bryant and M.J. Gardner), British Medical Journal, London, 171-190. [10]
6. Altman, D.G., Machin, D., Bryant, T.N. and Gardner, M.J. (eds) (2000) Statistics With Confidence, 2nd edn, British Medical Journal, London. [8]
7. Altman, D.G., Whitehead, J., Parmar, M.K.B., Stenning, S.P., Fayers, P.M., and Machin, D., (1995) Randomised consent designs in cancer clinical trials. European Journal of Cancer, 31A, 1934-1944. [14]
8. Ang, E.S.-W., Lee, S.-T., Gan, C.S.-G., See, P.G.-J., Chan, Y.-H., Ng, L.-H. and Machin, D., (2001) Evaluating the role of alternative therapy in burn wound management: randomized trial comparing Moist Exposed Burn Ointment with conventional methods in the management of patients with second-degree burns. Medscape General Medicine, 3 (2), 3. [2, 7, 12]
9. Ang, E.S.-W., Lee, S.-T., Gan, C.S.-G., Chan, Y.-H., Cheung, Y.-B. and Machin, D. (2003) Pain control in a randomized controlled trial comparing Moist Exposed Burn Ointment (MEBO) and conventional methods in patients with partial thickness burns. Journal of Burn Care and Rehabilitation, 24, 289-296. [4, 7]
10. Arrow, P. and Riordan, P.J. (1995) Retention and caries preventive effects of a GIC and a resinbased fissure sealant. Community Dentistry and Oral Epidemiology, 23, 282-285. [12]
11. ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet, 359, 2131-2139. [14]
12. Begg, C., Cho, M., Eastwood, S., Horton, R., Moher, D., Olkin, I., Pitkin, R., Rennie, D., Schultz, K.F., Simel, D. and Stroup, D.F. (1996) Improving the quality of reporting randomized controlled trials: the CONSORT statement. Journal of the American Medical Association, 276, 637-639. [2, 10]
13. Bellary, S., O'Hare, J.P., Raymond, N.T., Gumber, A., Mughal, S. , Szczepura, A. , Kumar, S. and Barnett, A.H. (2008) Enhanced diabetes care to patients of south Asian ethnic origin (the United Kingdom Asian Diabetes Study): a cluster randomised trial. Lancet, 371, 1769-1776. [11]
14. Berkowitz, S. (1998). Prerandomization of clinical trials: a more ethical way for performing cleft palate research. Plastic and Reconstructive Surgery, 102, 1724. [14]
15. Biostat (2001) Power & precision: release 2.1, Englewood, NJ. [9]
16. Birkett, M.A. and Day, S.J. (1994) Internal pilot studies for estimating sample size. Statistics in Medicine, 13, 2455-2463. [7]
17. Bladé, J., Samson, D., Reece, D., Apperley J, Björkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. and Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology, 102, 1115-1123. [4]
18. BMJ (2006) Editors' checklist, www.bmj.com/advice/checklists.shtml. [10]
19. Boutron, I., Moher, D., Altman, D.G., Schultz, K.F. and Ravaud, P. (2008) Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Annals of Internal Medicine, 148, 295-309. [10]
20. Bradburn, M.J., Clark, T.G., Love, S.B. and Altman, D.G. (2003) Survival analysis part III: multivariate data analysis-choosing a model and assessing its adequacy and fit. British Journal of Cancer, 89, 605-611. [10]
21. Brandes, A.A., Vastola, F., Basso, U., Berti, F., Inna, G., Rotilio, A., Gardiman, M., Scienza, R., Monfardini, S. and Ermani, M. (2003) A prospective study of glioblastoma in the elderly. Cancer, 97, 657-662. [1]
22. Brown, J., McElvenny, D., Nixon, J., Bainbridge, J. and Mason, S. (2000) Some practical issues in the design, monitoring and analysis of a sequential randomized trial in pressure sore prevention. Statistics in Medicine, 19, 3389-3400. [4, 14]
23. Bryant, T.N. (2000) Computer software for calculating confidence intervals (CIA) In Statistics with Confidence, 2nd edn (eds D.G. Altman, D. Machin, T.N. Bryant and M.J. Gardner), British Medical Journal, London, pp. 208-213. [10]
24. Calverley, P., Pauwels, R., Vestbo, J., Jones, P., Pride, N., Gulsvik, A., Anderson, J. and Maden, C. (2003) Combined salmeterol and flucticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, 361, 449-456. [13]
25. Campbell, G., Pickles, T. and D'yachkova, Y. (2003) A randomised trial of cranberry versus apple juice in the management of urinary symptoms during external beam radiation therapy for prostate cancer. Clinical Oncology, 15, 322-328. [5]
26. Campbell, M., Fitzpatrick, R., Haines, A., Kinmonth, A.L., Sandercock, P., Spiegelhalter, D. and Tyrer, P. (2000) Framework for design and evaluation of complex interventions to improve health. BMJ, 321, 694-696. [1]
27. Campbell, M.J. (2000) Cluster randomized trials in general (family) practice research. Statistical Methods in Medical Research, 9, 81-94. [11]
28. Campbell, M.J. and Gardner, M.J. (2000) Medians and their differences. In Statistics with Confidence, 2nd edn (eds D.G. Altman, D. Machin, T.N. Bryant and M.J. Gardner), British Medical Journal, London. [8]
29. Campbell, M.J., Machin, D. and Walters, S.J. (2007) Medical Statistics: a Commonsense Approach: a Text Book for the Health Sciences, 4th edn, John Wiley & Sons, Ltd, Chichester. [8]
30. Campbell, M.K., Elbourne, D.R. and Altman, D.G. for the CONSORT Group (2004) The CONSORT statement: extension to cluster randomised trials. British Medical Journal, 328, 702-708. [10]
31. Campbell, M.K., Fayers, P.M. and Grimshaw, J.M. (2005) Determinants of the intracluster correlation coefficient in cluster randomised trials. Clinical Trials, 2, 99-107. [11]
32. Chen, Z.M., Pan, H.C., Chen, Y.P., Peto, R., Collins, R., Jiang, L.X., Xie, J.X., Liu, L.S. (2005) Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet, 366, 1622-1632. [14]
33. Chow, P.K.-H., Tai, B.-C., Tan, C.-K., Machin, D., Johnson, P.J., Khin, M.-W. and Soo, K.-C. (2002) No role for high-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: an Asia-Pacific double-blind randomised controlled trial. Hepatology, 36, 1221-1226. [2, 3, 5, 10]
34. Clarke,M. (2006) The Cochrane Collaboration. In Textbook of Clinical Trials, Chapter 3, 2nd edn (eds D. Machin, S. Day and S. Green), John Wiley & Sons, Ltd, Chichester, pp. 39-46. [14]
35. Clarke, M., Hopewell, S. and Chalmers, I. (2007) Reports of clinical trials should begin and end with up-to-date systematic reviews of the other relevant evidence: a status report. Journal of the Royal Society of Medicine, 100, 187-190. [14]
36. Cohen, J. (1988) Statistical Power Analysis for the Behavioral Sciences, 2nd edn, Lawrence Erlbaum, New Jersey. [9, 10, 12, 11, 13]
37. Comi, G., Pulizzi, A., Rovaris, M., Abramsky, O., Arbizu, T., Boiko, A., Gold, R., Havrdova, E., Komoly, S., Selmaj, K.W., Sharrack, B. and Filippi, M. (2008) Effect of laquinimod on MRImonitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet, 371, 2085-2092. [4, 10]
38. Cox, D.R. (1972) Regression models and life tables (with discussion). Journal of the Royal Statistical Society B, 34, 187-220. [1]
39. CPMP Working Party on Efficacy of Medicinal Products (1995) Biostatistical methodology in clinical trials in applications for marketing authorizations for medicinal products. Statistics in Medicine, 14, 1659-1682. [14]
40. Craig, P., Dieppe, P.P., Macintyre, S., Mitchie, S., Nazarath, I. and Petticrew, M. (2008) Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ, 337, 979-983. [2]
41. Csendes, A., Burdiles, P., Korn, O., Braghetto, I., Huertas, C. and Rojas, J. (2002) Late results of a randomized clinical trial comparing total fundoplication versus calibration of the cardia with posterior gastropexy. British Journal of Surgery, 87, 289-297. [5]
42. Cuschieri, A., Weeden, S., Fielding, J., Bancewicz, J., Craven, J., Joypaul, V., Sydes, M. and Fayers, P. (1999) Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. British Journal of Cancer, 79, 1522-1530. [9]
43. DAMOCLES Study Group (2005) A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet, 365, 711-722. [7]
44. Day, S. (2007) Dictionary for Clinical Trials, 2nd edn, John Wiley & Sons, Ltd, Chichester. [1, 3, 6]
45. Day, S. and Småstuen, M. (2008) An open mind on adaptive designs. GCPj, December, Informa UK Ltd, pp. 19-22, www.GCPj.com.
46. De Angelis, C.D., Drazen, J.M., Frizelle, F.A., Haug, C., Hoey, J., Horton, R., Kotzin, S., Laine, C., Marusic, A., Overbeke, A.J.P.M., Schroeder, T.V., Sox, H.C. and Van Der Weyden, M.B. (2004) Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Annals of Internal Medicine, 141, 477-478. [6]
47. D'Haens, G., Baert, F., van Assche, G., Caenepeel, P., Vergauwe, P., Tuynman, H., De Vos, M., van Deventer, S., Stitt, L., Donner, A., Vermeire, S., Van De Mierop, F.J., Coche, J.-C.R., van der Woude, J., Ochsenkühn, T., van Bodegraven Ad, A., Van Hootengem, P.P., Lambrecht, G.L., Mana, F., Rutgeerts, P., Feagan, B.G. and Hommes, D. (2008) Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet, 371, 660-667. [10]
48. Dickersin, K. and Rennie, D. (2003) Registering clinical trials. Journal of the American Medical Association, 290, 516-523. [6, 10]
49. Donner, A. and Klar, N. (2000) Design and Analysis of Cluster Randomised Trials, Edward Arnold, London. [11]
50. Drucker, D.J., Buse, J.B., Taylor, K., Kendall, D.M., Trautmann, M. and Zhuang, D., for the DURATION-1 Study Group. (2008) Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet, 372, 1240-1250. [10]
51. Dupont, W.D. and Plummer, W.D. (1997) PS: power and sample size. Controlled Clinical Trials, 18, 274. [9, 10]
52. Edwards, S.J.L., Braunholtz, D.A., Lilford, R.J. and Stevens, A.J. (1999) Ethical issues in the design and conduct of cluster randomised controlled trials. BMJ, 318, 1407-1409. [11]
53. Egger, M., Davey-Smith, G. and Altman, D.G. (eds) (2001) Systematic Reviews in Health Care:Meta-Analysis in Context (2nd edn). BMJ Books, Oxford. [14]
54. Elbourne, D.R., Altman, D.G., Higgins, J.P.T., Curtin, F., Worthington, H.V. and Vail, A. (2002) Meta-analysis involving cross-over trials: methodological issues. International Journal of Epidemiology, 31, 140-149. [12]
55. Erbel, R., Di Mario, C., Bartunek, J., Bonnier, J., de Bruyne, B., Eberli, F.R., Erne, P., Haude, M., Heublein, B., Horrigan, M., Ilsley, C., Böse, D., Koolen, J., Lũscher, T.F., Weissman, N. and Waksman, R. (2007). Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet, 369, 1869-1875. [1, 2, 4, 5, 10]
56. Equi, A., Balfour-Lynn, I.M., Bush, A. and Rosenthal, M. (2002) Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet, 360, 978-984. [12]
57. Eron, J., Yeni, P., Gathe, J., Estrada, V., DeJesus, E., Staszewski, S., Lackey, P. and 9 others (2006) The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet, 368, 476-482. [11]
58. European Medicines Agency (EMEA), Committee for Medicinal Products for Human Use (CHMP) (2005) Guideline for Clinical Trials in Small Populations, www.emea.eu.int/pdfs/human/ewp/8356105en.pdf. [14]
59. European Medicines Agency (EMEA). (2009) Procedure for European Union Guidelines and Related Documents within the Pharmaceutical Legislative Framework. EMEA/P/24143/2004 Rev.1, EMEA, Canary Wharf, London. [1]
60. Fayers, P.M., Ashby, D. and Parmar, M.K.B. (1997) Bayesian data monitoring in clinical trials. Statistics in Medicine, 16, 1413-1430. [14]
61. Fayers, P.M., Jordhøy, M.S. and Kaasa, S. (2002) Cluster-randomized trials. Palliative Medicine, 16, 69-70. [11]
62. Fayers, P.M. and King, M. (2008) The baseline characteristics did not differ significantly. Quality of Life Research, 17, 1047-1048. [10]
63. Fayers, P.M. and Machin, D. (2007) Quality of Life: Assessment, Analysis and Interpretation of Patients-reported Outcomes, 2nd edn, John Wiley & Sons, Ltd, Chichester. [14]
64. Fitzpatrick, S. (2008a) Clinical Trial Design, ICR Publishing, Marlow, www.icr-global.org. [1]
65. Fitzpatrick, S. (2008b) The Clinical Trial Protocol, ICR Publishing, Marlow, www.icr-global.org. [1]
66. Fleiss, J.L. (1986) The Design and Analysis of Clinical Experiments, John Wiley & Sons Ltd, New York. [13, 14]
67. Food and Drug Administration (FDA) (1988) Guidelines for the Format and Content of the Clinical and Statistics Section of New Drug Applications. US Department of Health and Human Services, Public Health Service, Food and Drug Administration. [1]
68. Frech, S.A., DuPont, H.L., Bourgeois, A.L., McKenzie, R., Blekind-Gerson, J., Figueroa, J.F., Okhuysen, P.C., Geurrero, N.H., Martinez-Sandoval, FG., Meléndez-Romero, J.H.M., Jiang, Z.-D., Asturias, E.J., Halpern, J., Torres, O.R., Hoffman, A.S., Villar, C.P., Kassem, R.N., Flyer, D.C., Anderson, B.H., Kazempour, K., Breisch, S.A. and Glenn, G.M. (2008) Use of patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet, 371, 2019-2025. [10]
69. Freeman, J.V., Walters, S.J. and Campbell, M.J. (2008) How to Display Data. BMJ Books, Oxford. [1, 8]
70. Frison, L. and Pocock, S.J. (1992) Repeated measures in clinical trials: analysing mean summary statistics and its implications for design. Statistics in Medicine, 11, 1685-1704. [10]
71. Gagnier, J.J., Boon, H., Rochon, P., Moher, D., Barnes, J. and Bombardier, C. (2006) Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Annals of Internal Medicine, 144, 364-367. [10]
72. Gardner, M.J., Machin, D., Campbell, M.J. and Altman, D.G. (2000) Statistical checklists. In Statistics With Confidence, 2nd edn (eds D.G. Altman, D. Machin, T.N. Bryant and M.J. Gardner), British Medical Journal, London, pp. 191-201. [10]
73. Gerb, J. and Köpcke, W. (2007) The new EMEA-CHMP Guideline on Clinical Trials in Small Populations-Methodological and statistical considerations with published examples. Biocybernetics and Biomedical Engineering, 27, 59-66. [14]
74. Giles, F.J., Kantarjian, H.M., Cortes, J.E., Garcia-Manero, G., Verstovsek, S., Faderl, S., Thomas, D.A., Ferrajoli, A., O'Brien, S., Wathen, J.K., Xiao, L.-C., Berry, D.A. and Estey, E.H. (2003) Adaptive randomized study of Idarubicin and Cytarabine versus Troxacitabine and Cytarabine versus Troxacitabine and Idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. Journal of Clinical Oncology, 21, 1722-1727. [14]
75. Girard, T.D., Kress, J.P., Fuchs, B.D., Thomason J.W.W., Schweickert, W.D., Pun, B.T., Taichman, D.B., Dunn, J.G., Pohlman, A.S., Kinniry, P.A., Jackson, J.C., Canonico, A.E., Light, R.W., Shintani, A.K., Thompson, J.L., Gordon, S.M., Hall, J.B., Ditus, R.S., Bernard, G.R. and Ely, E.W. (2008) Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet, 371, 126-134. [10]
76. Girling, D.J., Parmar, M.K.B., Stenning, S.P., Stephens, R.J. and Stewart, L.A. (2003) Clinical trials in cancer, Oxford University Press, Oxford. [1]
77. Glaucoma Laser Trial Research Group (1995) The glaucoma laser trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology, 120, 10-22. [1]
78. Grobler, L., Siegfried, N., Askie, L., Hooft, L., Tharyan, P. and Antes, G. (2008) National and multinational prospective trial registers. Lancet, 372, 1201-1202. [6]
79. Hancock, M.J., Maher, C.G., Latimer, J., McLachlan, A.J., Cooper, C.W., Day, R.O., Spindler, M.F. and McAuley, J.H. (2007) Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first-line treatment for acute low back pain: a randomised controlled trial. Lancet, 370, 1638-1643. [10, 13]
80. Hay, A.D., Costelloe, C., Redmond, N.M., Montgomery, A.A., Fletcher, M., Hollinghurst, S. and Peters, T.J. (2008) Paracetemol plus ibuprofen for the treatment of fever in children (PITCH): randomised controlled trial. BMJ, 337, a1302, doi: 10.1136/bmj.a1302. [2, 10]
81. Higgins, J.P.T. and Green, S. (eds) (2005) Cochrane Handbook for Systematic Reviews of Interventions 4.2.4 [updated March 2005]. In The Cochrane Library, Issue 2, John Wiley & Sons, Ltd, Chichester. [1, 14]
82. Hopewell, S., Clarke, M., Moher, D., Wager, E., Middleton, P. and Altman, D.G. (2008) CONSORT for reporting randomised trials in journal and conferences abstracts. Lancet, 371, 281-283. [10]
83. Huibers, M.J., Bleijenberg, G., Beurkens, A.J., Kant, I.J., Knottnerus, J.A., van der Windt, D.A., Bazelmans, E. and van Schayck, C.P. (2004) An alternative trial design to overcome validity and recruitment problems in primary care research. Family Practice, 21, 213-218. [14]
84. Hujoel, P.P. (1998) Design and analysis issues in split mouth clinical trials. Community Dentistry and Oral Epidemiology, 26, 85-86. [12]
85. Hujoel, P.P. and Moulton, L.H. (1988) Evaluation of test statistics in split mouth clinical trials. Journal of Periodontal Research, 23, 378-386. [12]
86. ICH E2A (1994) Clinical safety data management: definitions and standards for expedited reporting. CPMP/ICH/377/95, EMEA, Canary Wharf, London, www.emea.eu.int. [6]
87. ICH E2B(M) (2000) Note for guidance on clinical safety data management: data elements for transmission of individual case safety reports. CPMP/ICH/287/95, EMEA, Canary Wharf, London, www.emea.eu.int. [6]
88. ICH E3 (1995) Structure and content of clinical study reports. CPMP/ICH/137/95, EMEA, Canary Wharf, London, www.emea.eu.int. [6, 10]
89. ICH E6 (R1) (1996) Guideline for good clinical practice. CPMP/ICH/135/95, EMEA, Canary Wharf, London, www.emea.eu.int. [1, 3, 4, 5, 6]
90. ICH E8 (1997) General considerations for clinical trials. CPMP/ICH/291/95, EMEA, Canary Wharf, London, www.emea.eu.int. [6]
91. ICH E9 (1998) Statistical principles for clinical trials. CPMP/ICH/363/96, EMEA, Canary Wharf, London, www.emea.eu.int. [1, 4, 5, 6]
92. ICH E9 Expert Working Group (1999) Statistical principles for clinical trials: ICH Harmonised Tripartite Guideline, Statistics in Medicine, 18, 1905-1942. [1, 2, 4, 5, 6, 9]
93. ICH E10 (2000) Choice of control group in clinical trials. CPMP/ICH/2711/99, EMEA, Canary Wharf, London, www.emea.eu.int. [2, 6]
94. Institute of Clinical Research (2008) The Fundamental Guidelines for Clinical Research V2.0, ICR Publishing. [1, 2, 3]
95. Ioannidis, J.P., Evans, S.J., Gotzsche, P.C., O'Neill, R.T., Altman, D.G., Schultz, K. et al. (2004) Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine, 141, 781-788. [10]
96. Jadad, A. (1998) Randomised Controlled Trials, British Medical Journal, London. [1]
97. James, N.D., Sydes, M.R., Clarke, N.W., Mason, M.D., Dearnaley, D.P., Anderson, J., Popert, R.J., Sanders, K., Morgan, R.C., Stansfeld, J., Dwyer, J., Masters, J. and Parmar, M.K.B. (2008) STAMPEDE: systemic therapy for advancing or metastatic prostate cancer-a multi-arm multi-stage randomised controlled trial. Clinical Oncology, 20, 577-581. [7, 14]
98. Jenni, S., Oetliker, C., Allemann, S., Ith, M., Tappy, L., Wuerth, S., Egger, A., Boesch, C., Schneiter, Ph., Diem, P., Christ, E. and Stettler, C. (2008) Fuel metabolism during exercise in euglycaemia and hyperglycaemia in patients with type 1 diabetes mellitus-a prospective single-blind randomised crossover trial. Diabetologia, 51, 1457-1465. [12]
99. Jensen, P.T., Klee, M.C., Thranov, I. and Groenvold, M. (2004) Validation of a questionnaire for self-assessment of sexual function and vaginal changes after gynaecological cancer. Psycho-Oncology, 13, 577-592. [4]
100. Jones, B. (2008) The cross-over trial: a subtle knife. Significance, 5, 135-137. [12]
101. Jones, B., Jarvis, P., Lewis, J.A. and Ebbutt, A.F. (1996) Trials to assess equivalence: the importance of rigorous methods. British Medical Journal, 313, 36-39. [11]
102. Jordhøy, M.S., Fayers, P.M.,Ahlner-Elmqvist, M. and Kaasa S. (2002) Lack of concealment may lead to selection bias in cluster randomized trials of palliative care. Palliative Medicine, 16, 43-49. [11]
103. Jüni, P., Altman, D.G. and Egger, M. (2001). Assessing the quality of controlled clinical trials. BMJ, 323, 42-46. [14]
104. Kahn, R.S., Fleischhacker, W.W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I.P.M. and 13 others (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet, 371, 1085-1097. [2, 10, 13]
105. Kaplan, E.L. and Meier, P. (1958) Non parametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481. [1]
106. Kohler, J.A., Imeson, J., Ellershaw, C. and Lie, S.O. (2000) A randomized trial of 13-cis retinoic acid in children with advanced neuroblastoma after high-dose therapy. British Journal of Cancer, 83, 1124-1127. [8]
107. Krishna, R., Anderson, M.S., Bergman, A.J., Jin, B., Fallon, M., Cote, J., Rosko, K., Chavez-Eng, C., Lutz, R., Bloomfield, D.M., Gutierrez, M., Doherty, J., Bieberdorf, F., Chodakewitz, J., Gottesdiener, K.M. and Wagner, J.A. (2007) Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomized placebocontrolled phase I studies. Lancet, 370, 1907-1914. [1, 2, 10, 12]
108. Larsson, P.-G. and Carlsson, B. (2002) Does pre-and postoperative metronidazole treatment lower vaginal cuff infection rate after abdominal hysterectomy among women with bacterial vaginosis? Infectious Diseases in Obstetrics and Gynecolgy, 10, 133-140. [10, 14]
109. Lau, W.Y., Lai, E.C.H., Leung, T.W.T. and Yu, S.C.H. (2008) Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trialupdate on 5-year and 10-year survival. Annals of Surgery, 247, 43-48. [7]
110. Lau, W.Y., Leung, T.W.T., Ho, S.K.W., Chan, M., Machin, D., Lau, J., Chan, A.T.C., Yeo, W., Mok, T.S.K., Yu, S.C.H., Leung, N.W.Y. and Johnson, P.J. (1999) Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet, 353, 797-801. [7, 8, 10]
111. Lenth, R.V. (2006) Java Applets for Power and Sample Size. www.stat.uiowa.edu/~rlenth/Power. [9]
112. Levie, K., Gjorup, I., Skinhøj, P. and Stoffel, M. (2002) A 2-dose regimen of recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of EnderixTM-B in healthy young adults. Scandinavian Journal of Infectious Disease, 34, 610-614. [1]
113. Levy,H.L., Milanowski, A., Chakrapani,M., Cleary,M., Lee, P., Trefz, FK.,Whitley,C.B., Feillet, F., Feigenbaum, A.S., Bebchuk, J.D., Christ-Schmidt, H. and Dorenbaum, A. (2007) Efficacy of sepropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet, 370, 504-510. [11]
114. Llovet, J.M., Real, M.I., Montaňa, X., Planas, R., Coll, S., Aponte, J., Ayuso, C., Sala, M., Muchart, J., Solà , R., Rodés, J. and Bruix, J. (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet, 359, 1734-1739. [14]
115. Lo, E.C.M., Luo, Y., Fan, M.W. and Wei, S.H.Y. (2001) Clinical investigation of two glass-ionomer restoratives used with the atraumatic restorative treatment approach in china: two-years results. Caries Research, 35, 458-463. [1, 5, 10, 12]
116. Lo, E.C.M., Luo, Y., Tan H.P., Dyson, J.E. and Corbet, E.F. (2006). ART and conventional root restorations in elders after 12 months. Journal of Dental Research, 85, 929-932. [5]
117. Lobo, D.N., Bostock, K.A., Neal, K.R., Perkins, A.C., Rowlands, B.J. and Allison, S.P. (2002) Effect of salt and water balance on recovery of gastrointestinal function after elective colonic resection: a randomised controlled trial. Lancet, 359, 1812-1818. [1, 9]
118. Machin, D., Campbell, M.J., Tan, S.B. and Tan, S.H. (2009) Sample Sizes Tables for Clinical Studies, 3rd edn, Wiley-Blackwell, Oxford. [1, 3, 9, 10, 12]
119. Machin, D., Cheung, Y.B. and Parmar, M.K.B. (2006) Survival Analysis: a Practical Approach, 2nd edn, John Wiley & Sons, Ltd, Chichester. [8]
120. Machin, D., Day, S. and Green, S. (eds) (2006) Textbook of Clinical Trials, 2nd edn, John Wiley & Sons, Ltd, Chichester. [1]
121. Machin, D. and Lee, S.T. (2000) The ethics of randomization trials in the context of cleft palate research. Plastic and Reconstructive Surgery, 105, 1566-1568. [14]
122. Machin, D., Stenning, S.P., Parmar, M.K.B., Fayers, P.M., Girling, D.J., Stephens, R.J., Stewart, L.A. and Whaley, J.B. (1997) Thirty years of Medical Research Council randomized trials in solid tumours. Clinical Oncology, 9, 20-28. [2]
123. McMurray, J.J.V.,ö stergren, J., Swedberg, K. Granger, C.B., Held, P., Mivhelson, E.L., Olofsson, B., Yusuf, S., Pfeffer, M.A. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet, 362, 767-771. [14]
124. Medical Research Council (2002) Cluster Randomised Trials: Methodological and Ethical Considerations, MRC Clinical Trials Series, Medical Research Council, London. [11]
125. Medical Research Council Lung Cancer Working Party (1996) Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Clinical Oncology, 8, 167-175. [2]
126. Medical Research Council Whooping-Cough Immunization Committee (1951) The prevention of whooping-cough by vaccination. British Medical Journal, 1, 1463-1471. [1]
127. Meggitt, S.J., Gray, J.C. and Reynolds, N.J. (2006) Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet, 367, 839-846. [1, 2, 4, 8, 9, 10, 11, 12]
128. Meyer,G.,Warnke,A., Mülhauser, I. and Bender, R. (2003) Effect on hip fractures of increased use of hip protectors in nursing homes: cluster randomised controlled trial. BMJ, 326, 76-78. [1, 2, 11]
129. Mitchell, C., Jones, K.P., Shannon, R., Hutton, C., Stevens, S., Machin, D., Imeson, J., Kelsey, A., Vujanic, G.M., Gornall, P., Walker, J., Taylor, R., Sartori, P., Hale, J., Levitt, H.G., Msahael, B., Middleton, H., Grundy, R.G. and Pritchard, J. (2006) Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumour: Results of a randomised trial (UKW3) by the UK Children's Cancer Study Group. European Journal of Cancer, 42, 2554-2562. [10]
130. Moher, D., Cook, D.J., Eastwood, S., Olkin, I., Rennie, D., and Stroup, D.F. (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet, 354, 1896-1900. [14]
131. Moher, D., Schultz, K.F. and Altman, D.G., for the CONSORT Group (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet, 357, 1191-1194. [1, 2, 5, 10]
132. Motzer, R.J., Escudier, B., Oudard, S., Hutson, T.E., Porta, C., Bracardo, S., Grünwald, V., Thompson, J.A., Figlin, R.A., Hollaender, N., Urbanowitz, G., Berg, W.J., Kay, A., Lebwohl, D. and Ravaud, A. (2008) Efficacy of everolimus in advanced renal cell carcinoma: a doubleblind, randomised, placebo-controlled phase III trial. Lancet, 372, 449-456. [10]
133. Muers, M.F., Stephens, R.J., Fisher, P., Darlison, L., Higgs, C.M.B., Lowry, L., Nicholson, A.G., O'Brien, M. and 8 others (2008) Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre trial. Lancet, 371, 1685-1694. [13]
134. National Cancer Institute (2003) Common Terminology Criteria for Adverse Events. (v3.0 CTCAE), National Cancer Institute, Bethesda, www.ctep.cancer.gov/reporting/ctc.html. [3]
135. National Council for Social Studies (2005) Power analysis and sample size software (PASS): Version 2005, Kaysville, UT. [9]
136. Newcombe, R.G. and Altman, D.G. (2000) Proportions and their differences. In Statistics with Confidence, 2nd edn (eds D.G. Altman, D. Machin, T.N. Bryant and M.J. Gardner), British Medical Journal Books, London, pp. 45-56. [8]
137. Nixon, J., McElvenny D., Mason, S., Brown, J. and Bond, S. (1998) A sequential randomised controlled trial comparing a dry visco-elastic polymer gel pad and standard operating table mattresses in the prevention of post-operative pressure sores. International Journal of Nursing Studies, 35, 193-203. [10, 14]
138. Oliver, P.C., Crawford, M.J., Rao, B., Reece, B. and Tyrer, P. (2007) Modified overt aggression scale (MOAS) for people with intellectual disability and aggressive challenging behaviour: a reliability study. Journal of Applied Research in Intellectual Disability, 20, 368-272. [10]
139. Palumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V., Callea, V., Cangialosi, C., Grasso, M., Rossini, F., Galli, M., Catalano, L., Zamagni, E., Petrucci, M.T., De Stefano, V., Ceccarelli, M., Ambrosini, M.T., Avonto, I., Falco, P., Ciccone, G., Liberati, A.M., Musto, P. and Boccadoro, M. (2006) Oral melaphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet, 367, 825-831. [4, 9]
140. Papp, K., Bissonnette, R., Rosoph, L., Wasel, N., Lynde, C.W., Searles, G., Shear, N.H., Huizinga, R.B. and Maksymowych, W.P. (2008) Efficacy of ISA247 in plaque psoriasis: a randomised multicentre, double-blind, placebo-controlled phase III study. Lancet, 371, 1337-1342. [13]
141. Parmar, M.K.B., Barthel, F.M.-S., Sydes, M., Langley, R., Kaplan, R., Eisenhauer, E., Brady, M., James, N., Bookman, M.A., Swart, A.-M., Qian, W. and Royston, P. (2008) Speeding up the evaluation of new agents in cancer. Journal of the National Cancer Institute, 100, 1204-1214. [4, 14]
142. PEST (2004) Operating Manual 4.4, MPS Research Unit, University of Reading, Reading. [14]
143. Peters, T.J., Richards, S.H., Bankhead, C.R., Ades, A.E. and Sterne, J.A.C. (2003) Comparison of methods for analysing cluster randomized trials: an example involving a factorial design. International Journal of Epidemiology, 32, 840-846. [11]
144. Peto, R., Pike, M.C., Armitage, P., Breslow, N.E., Cox, D.R., Howard, S.V., Mantel, N., McPherson, K., Peto, J. and Smith, P.G. (1976) Design and analysis of randomized clinical trials requiring prolonged observation of each patient (I) Introduction and design. British Journal of Cancer, 34, 585-612. [1]
145. Peto, R., Pike, M.C., Armitage, P., Breslow, N.E., Cox, D.R., Howard, SV., Mantel, N., McPherson, K., Peto, J. and Smith, P.G. (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient (II) Analysis and examples. British Journal of Cancer, 35, 1-39. [1]
146. Phillips, A. (2006) Flexibility by design, GCPj, Informa UK Ltd, July, pp. 13-17, www.GCPj.com [14]
147. Piaggio, G., Carolli, G., Villar, J., Bakketeig, L., Lumbiganon, P., Bergsjø, P., Al-Mazrou, Y., Ba'aqeel, H., Belizán, J.M., Farnot, U. and Berendes, H. (2001) Methodological considerations on the design and analysis of an equivalence stratified cluster randomization
148. Piaggio, G., Elbourne, D.R., Altman, D.G., Pocock, S.J. and Evans, S.J.W. (2001) Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. Journal of the American Medical Association, 295, 1152-1160. [10, 11]
149. Piaggio, G. and Pinol, A.P. (2001) Use of the equivalence approach in reproductive health clinical trials. Statistics in Medicine, 20, 3571-3577. [11]
150. Pocock, S.J. (1983) Clinical Trials: a Practical Approach, John Wiley & Sons, Ltd, Chichester. [1, 8]
151. Pocock, S.J. and Ware, J.E. (2009) Translating statistical findings into plain English. Lancet, 373, 1926-1928. [10]
152. Pocock, S.J. and White, I. (1999) Trials stopped early: too good to be true? Lancet, 353, 943-944. [7]
153. Poon, C.Y., Goh, B.T., Kim,M.-J., Rajaseharan, A., Ahmed, S., Thongsprasom, K., Chaimusik,M., Suresh, S., Machin, D., Wong-H.B. and Seldrup, J. (2006) A randomised controlled trial to compare steroid with cyclosporine for the topical treatment of oral lichen planus. Oral Surgery, Oral Medicince, Oral Pathology, Oral Radiololgy and Endodontology, 102, 47-55. [2, 3, 7, 8, 10, 12]
154. Quaranta, L., Pizzolante, T., Riva, I., Haidich, A.-B., Konstas, G.P. and Stewart, W.C. (2008) Twenty-four-hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normal-tension glaucoma. British Journal of Ophthalmology, 92, 1227-1231. [12]
155. Redwood, C. and Colton, T. (eds) (2001) Biostatistics in Clinical Trials, John Wiley & Sons, Ltd, Chichester. [1]
156. Regidor, E., Barrio, G., de la Feunte, L., Domingo, A. and Alonso, J. (1999) Association between educational level and health related quality of life in Spanish adults. Journal of Epidemiology and Community Health, 53, 75-82. [11]
157. SAS Institute (2004) Getting Started with the SAS Power and Sample Size Application: Version 9.1, SAS Institute, Cary, NC. [9]
158. Schoenfeld, D. (1982) Partial residuals for the proportional hazards regression model. Biometrika, 69, 239-241. [10]
159. Scott, N.W., McPherson, G.C., Ramsay, C.R. and Campbell, M.K. (2002) The method of minimization for allocation to clinical trials. Controlled Clinical Trials, 23, 662-674. [5]
160. Schottenfeld, R.S., Charwarski, M.C. and Mazlan, M. (2008) Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, doubleblind, placebo controlled trial. Lancet, 371, 2192-2200. [13]
161. Senn, S.J. (2002) Cross-Over Trials in Clinical Research, 2nd edn, John Wiley & Sons, Ltd, Chichester. [12]
162. Senn, S. (2007) Statistical Issues in Drug Development, 2nd edn, John Wiley & Sons, Ltd, Chichester. [1]
163. Singapore Lichen Planus Study Group (2004) A randomized controlled trial to compare calcipotriol with betamethasone valerate for the treatment of cutaneous lichen planus. Journal of Dermatological Treatment, 15, 141-145. [10]
164. Smith, I., Procter,M.,Gelber, R.D.,Guillaume,S., Feyereislova,A.,Dowsett,M.,Goldhirsch,A.,Untch, M., Mariani, G., Baselga, J.,Kaufmann,M., Cameron, D., Bell, R., Bergh, J., Coleman, R.,Wardley, A., Harbeck, N., Lopez, RI., Mallmann, P., Gelmon, K., Wilcken, N., Wist, E., Rovira, P.S. and Piccart-Gebhart, M.J. (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet, 369, 29-36. [1, 5, 10]
165. Smolen, J.S., Beaulieu, A., Rubbert-Roth, A., Ramos-Remus, C., Rovensky, J., Alecock, E., Woodworth, T., and Alten, R. (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (Option study): a double-blind, placebocontrolled, randomised trial. Lancet, 371, 987-997. [10, 13]
166. Spiegelhalter, D.J., Freedman, L.S. and Parmar, M.K.B. (1994) Bayesian approaches to randomized trials (with discussion). Journal of the Royal Statistical Society A, 157, 357-416. [14]
167. Sprangers, M.A., Cull, A. and Groenvold, M. (1998) EORTC Quality of Life Study Group: Guidelines for Developing Questionnaire Modules, EORTC, Brussels. [2, 4]
168. StataCorp (2007) Stata Statistical Software: Release 10, Stata Press, College Station, Texas. [8, 9, 10]
169. Statistical Solutions (2006) NQuery Advise: Version 6.0, Saugus, MA. [9]
170. Stevinson, C., Devaraj, V.S., Fountain-Barber, A., Hawkins, S. and Ernst, E. (2003) Homeopathic arnica for prevention of pain and bruising: randomized placebo-controlled trial in hand surgery. Journal of the Royal Society of Medicine, 96, 60-65. [1, 2, 5, 9, 10, 13]
171. Szefler, S.S., Mitchell, H., Sorkness, C.A., Gergen, P.J., O'Connor, G.T., Morgan, W.J., Kattan, M. and 10 others (2008) Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet, 372, 1065-1072. [10]
172. Tan, S.B., Chung, Y.F.A., Tai, B.C., Cheung, Y.B. and Machin, D. (2003) Elicitation of prior distributions for a phase III randomized controlled trial of adjuvant therapy with surgery for hepatocellular carcinoma. Controlled Clinical Trials, 24, 110-121. [14]
173. Tan, S.B., Dear, K.B.G., Bruzzi, P. and Machin, D. (2003) Strategy for randomised clinical trials in rare cancers. British Medical Journal, 327, 47-49. [14]
174. Tan, S.B., Wee, J., Wong, H.B. and Machin, D. (2008) Can external and subjective information ever be used to reduce the size of a randomised controlled trial? Contemporary Clinical Trials, 29, 211-219. [14]
175. Tang, C.-L., Eu, K.-W., Tai, B.-C., Soh, J.G.S., Machin, D. and Seow-Choen, F. (2001) Randomized clinical trial of the effect of open versus laparoscopically assisted colectomy on systemic immunity in patients with colorectal cancer. British Journal of Surgery, 88, 801-807. [4]
176. Tyrer, P., Oliver-Africano, P.C., Ahmed, Z., Bouras, N., Cooray, S., Deb, S., Murphy, D., Hare, M., Meade, M., Reece, B., Kramo, K., Bhaumik, S., Harley, D., Regan, A., Thoma, D., Rao, B., North, B., Eliahoo, J., Karatela, S., Soni, A. and Crawford, M. (2008) Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. Lancet, 371, 57-63. [10, 13]
177. Ukoumunne, O.C., Gulliford, M.C., Chinn, S., Sterne, J.A.C., Burney, P.G.J. (1999) Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment, 3(5), www.hta.ac.uk/fullmono/mon305.pdf. [11]
178. van der Meché, F.G.A. and Schmitz, P.I.M. (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. New England Journal of Medicine, 326, 1123-1129. [10]
179. Wang, D. and Bakhai, A. (eds) (2006) Clinical Trials. A Practical Guide to Design, Analysis and Reporting, Remedica, London. [1]
180. Ware, J.E., Snow, K.K., Kosinski, M. and Gandek, B. (1993) SF-36 Health Survey Manual and Interpretation Guide, New England Medical Centre, Boston, MA. [4]
181. Wee, J.T.S., Tan, E.H., Tai, B.C., Wong, H.-B., Leong, S.S., Tan, T., Chua, E.-T., Yang, E., Lee, K.M., Fong, K.W., Khoo, H.S., Lee, K.S., Loong, S., Sethi, V., Chua, E.J. and Machin, D. (2005) Randomized trial of radiotherapy versus concurrent chemo-radiotherapy followed by adjuvant chemotherapy in patients with AJCC/UICC (1997) stage III and IV nasopharyngeal cancer of the endemic variety. Journal of Clinical Oncology, 23, 6730-6738. [2, 4, 10, 14]
182. Weng, J., Li, Y., Xu, W., Shi, L., Zhang, Q., Zhu, D., Hu, Y. and Zhou, Z. and others (2008) Effect of intensive insulin therapy on Β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet, 371, 1753-1760. [1, 13]
183. Whitehead, J. (1997) The Design and Analysis of Sequential Clinical Trials, revised 2nd edn, John Wiley & Sons, Ltd, Chichester. [14]
184. WHO (2008) WHO International Clinical Trials Registry Platform: Universal Trial Reference Number (UTRN), www.who.int/ictrp/utrn/en/index.html. [6]
185. Williams, H.C., Burney, P.G., Hay, R.J., et al. (1994) The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis: I. Derivation of a minimum set of discriminators for atopic dermatitis. British Journal of Dermatology, 131, 383-396. [2]
186. Wright, J.R., Bouma, S., Dayes, I., Simunovic, M.R., Levine, M.N. and Whelan, T.J. (2006) The importance of reporting patient recruitment details in Phase III trials. Journal of Clinical Oncology, 24, 843-845. [2]
187. Yeow, V.K.-L., Lee, S.-T., Cheng, J.J., Chua, K., Wong, H.-B. and Machin, D. (2007) Randomised clinical trials in plastic surgery: survey of output and quality of reporting (letter). Journal of Plastic and Reconstructive Surgery, 60, 965-966. [1, 2, 7, 13]
188. Young, T., de Haes, J.C.J.M., Curran, D., Fayers, P.M. and Brandberg, Y. (1999) Guidelines for Assessing Quality of Life in EORTC Trials, EORTC, Brussels. [14]
189. Zelen, M. (1979) A new design for randomized clinical trials. New England Journal of Medicine, 300, 1242-1245. [14]
190. Zelen, M. (1992) Randomised consent trials. Lancet, 340, 375. [14]
191. Zheng, J.-P., Kang, J., Huang, S.-G., Chen, P., Yao, W.-Z., Yang, L., Bai, C.-X., Wang, C.-Z., Wang, C., Chen, B.-Y., Shi, Y., Liu, C.-T., Chen, P., Li, Q., Wang, Z.-S., Huang, Y.-J., Luo, Z.-Y., Chen, F.-P., Yuan, J.-Z., Yuan, B.-T., Qian, H.-P., Zhi, R.-C. and Zhong, N.-S. (2008) Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE study): a randomised placebo-controlled study. Lancet, 371, 2013-2018. [10]
192. Zongo, I., Dorsey, G., Rouamba, N., Tinto, H., Dokomajilar, C., Guiguemde, R.T., Rosenthal, P. and Ouedraogo, J.B. (2007) Artemether-lumefantrine versus amodiaquine plus sulfadoxinepyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised noinferiority trial. Lancet, 369, 491-498. [1, 5, 11]
193. Zwarenstein, M., Treweek, S., Gagniere, J.J., Altman, D.G., Tunis, S., Haynes, B., Oxman, A.D. and Moher, D. (2008) Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ, 337, 1223-1226. [10]